IMG has announced a partnership with DAZN for the FIFA Club World Cup 2025. The sports marketing agency will host DAZN’s global content operations for the tournament at its Stockley Park virtual ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why I downgraded GILD stock to Hold.

Gilead's dominance in HIV faces Medicare pricing challenges, limiting growth.

Medical pioneer Gilead Sciences (GILD) has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks.

Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention drugs Truvada and Descovy, according to a Wednesday filing in Delaware federal court.

Gilead must be held accountable for the harm caused by ‘patent hopping’ an HIV treatment Editorial boards claim the suit could destroy the pharmaceutical industry’s ability to innovate.

Stockley Park, UK – 3 June 2024 – Kite, a Gilead Company, announced data from a pilot study in collaboration with Dana-Farber Cancer Institute, that demonstrate Yescarta ® (axicabtagene ciloleucel) is ...

Gilead dealt a final blow to its anti-CD47 monoclonal antibody magrolimab Thursday by removing the remaining solid tumor trials from its pipeline.

Gilead Sciences Inc.’s stock dipped 0.2% in after-hours trading Thursday, after the drug company’s adjusted first-quarter profit was narrower than expected.

Gilead Sciences plans to quadruple cell therapy cancer treatment production by 2026. With a focus on CAR-T treatments like Yescarta and Tecartus, Gilead aims to diversify into oncology ...

Gilead, a global pharmaceutical company, acquired MiroBio, an Oxford-backed research company, in 2022. Gilead is headquartered in Foster City, California, with additional UK sites in central London, ...